Physician profile
Michael G Wiggins
NPI 1528040326
$2,128.93
in general payments reported to CMS, 2019-2025
16 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $407 · 2022: $543 · 2023: $134 · 2024: $630 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $409.47 | 2022-2024 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $353.11 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $344.13 | 2021-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $343.91 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $149.34 | 2022 | |
| Glaxosmithkline, LLC. | $144.18 | 2021-2022 | |
| Lilly USA, LLC | $112.57 | 2021-2023 | Emgality, Jardiance |
| Inspire Medical Systems, INC. | $105.34 | 2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $50.54 | 2024 | Opsumit |
| Vanda Pharmaceuticals INC. | $20.47 | 2024 | Fanapt |
| Esperion Therapeutics, INC. | $19.49 | 2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $18.44 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.62 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.31 | 2023 | Ajovy |
| Janssen Biotech, INC. | $13.22 | 2024 | Tremfya |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wiggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.